RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..4 of 4 - per page
Order by
Sensitive Antibody-based Assay for the Measurement of c-Met Concentration Shed in Bodily Fluids Useful in the Diagnosis and Prognosis of Cancer
Methods and assays which may be used to diagnose and follow the progression of cancers associated with c-Met expression More
A New Mouse Monoclonal Antibody Against Human Microphthalmia Transcription Factor (MITF)
This technology involves the generation of several novel mouse monoclonal antibodies against a sub-domain of an MITF fragment that is cleaved during cell death. More
Use of Anthrax Lethal Factor to Treat Cancer and Screening Methods for MAPK Kinase Protease Activity
In vitro and ex vivo methods of screening for modulators, homologues, and mimetics of LF mitogen activated protein kinase kinase (MAPKK) protease activity. More
Non-radioactive method to quantify acid ceramidase, applicable to diagnosis of Farber disease and tumours associated with its altered expression
Lysosomal acid ceramidase alteration is related to Farber disease and probably to cancer. We offer a fast and sensitive (pmol) fluorimetry method – current methods use radioactivity – to measure its level, with no interferences from other ceramidases More
Displaying 1..4 of 4 - per page
Order by

Related Reports

Market Research Reports provided by reports.innovaro.com
Skin Cancer and Melanoma Therapy Area Pipeline Report
Nov 2010 - 639 pages - $1,495
FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade
Apr 2011 - 5 pages - $500
Metastatic Melanoma Global Clinical Trials Review, Q4, 2010
Dec 2010 - 74 pages - $1,000
US Oncology, Inc. - SWOT Analysis
Nov 2010 - 26 pages - $125
Melanoma Global Clinical Trials Review, H2 2011
Sep 2011 - 109 pages - $1,000
US Oncology, Inc.: SWOT Analysis & Company Profile
Dec 2010 - 19 pages - $99
Nonmelanomatous Skin Cancer - Pipeline Review, Q4 2010
Dec 2010 - 26 pages - $500
Advancing Molecular Diagnostics to Personalize Cancer Therapy
Jun 2011 - 187 pages - $3,835
Molecular Targeted Cancer Therapies Market Forecast
Aug 2009 - $15,200
Pipeline Insight: Cancer Overview Malignant Melanoma, Neuroendocrine Tumors and Thyroid Cancer - New drug approvals likely after decades of little progress
Dec 2010 - 269 pages - $11,400
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2012 Innovaro Europe Ltd Innovaro Corporation All rights reserved. Terms and Conditions | Contact us